Skip to main content
SpringerLink
Log in

Capecitabine

A Viewpoint by Joanne L. Blum

  • Adis New Drug Profile
  • Guest Commentary
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485–93

    PubMed  CAS  Google Scholar 

  2. Blum JL, Buzdar AU, Dieras V, et al. A multicenter phase II trial of Xeloda™ (capecitabine) in taxane-refractory metastatic breast cancer. Proc Am Assoc Clin Oncol. In press

  3. O’Shaughnessy J, Moiseyenko V, Bell D, et al. A randomized phase II study of Xeloda™ (capecitabine) vs CMF as first line chemotherapy of breast cancer in women aged greater than or equal to 55 years. Proc Am Soc Clin Oncol 1998; 17: 103a

    Google Scholar 

  4. Moiseyenko V, O’Reilly SM, Talbot DC, et al. A randomized phase II study of Xeloda™ (capecitabine) vs paclitaxel in breast cancer patients failing previous anthracycline therapy [abstract]. Ann Oncol 1998; 9 (Suppl. 4): 13

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Baylor-Charles A. Sammons Cancer Center, Dallas, Texas, USA

    Joanne L. Blum

Authors
  1. Joanne L. Blum
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Blum, J.L. Capecitabine. Drugs 58, 77 (1999). https://doi.org/10.2165/00003495-199958010-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199958010-00007

Search

Navigation